KBC Group NV increased its position in shares of bluebird bio Inc (NASDAQ:BLUE) by 16.7% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 11,168 shares of the biotechnology company’s stock after buying an additional 1,599 shares during the quarter. KBC Group NV’s holdings in bluebird bio were worth $1,753,000 at the end of the most recent reporting period.
Other hedge funds have also recently added to or reduced their stakes in the company. Raymond James & Associates raised its stake in bluebird bio by 27.8% during the 4th quarter. Raymond James & Associates now owns 4,801 shares of the biotechnology company’s stock valued at $855,000 after purchasing an additional 1,045 shares during the last quarter. Millennium Management LLC acquired a new position in shares of bluebird bio in the 4th quarter valued at $2,613,000. Wells Fargo & Company MN raised its stake in shares of bluebird bio by 7.7% in the 1st quarter. Wells Fargo & Company MN now owns 83,400 shares of the biotechnology company’s stock valued at $14,240,000 after buying an additional 5,987 shares in the last quarter. Daiwa Securities Group Inc. raised its stake in shares of bluebird bio by 7.3% in the 1st quarter. Daiwa Securities Group Inc. now owns 11,209 shares of the biotechnology company’s stock valued at $1,914,000 after buying an additional 765 shares in the last quarter. Finally, NuWave Investment Management LLC increased its position in shares of bluebird bio by 117.0% during the 1st quarter. NuWave Investment Management LLC now owns 1,656 shares of the biotechnology company’s stock worth $287,000 after purchasing an additional 893 shares in the last quarter. 98.45% of the stock is currently owned by hedge funds and other institutional investors.
Shares of NASDAQ BLUE traded up $5.00 during mid-day trading on Tuesday, hitting $153.00. The company’s stock had a trading volume of 862,200 shares, compared to its average volume of 800,267. The firm has a market capitalization of $8.21 billion, a PE ratio of -19.29 and a beta of 1.86. bluebird bio Inc has a one year low of $119.90 and a one year high of $236.17.
BLUE has been the subject of a number of recent analyst reports. Cantor Fitzgerald reiterated an “underweight” rating on shares of bluebird bio in a research report on Wednesday, May 16th. Piper Jaffray Companies initiated coverage on shares of bluebird bio in a research report on Wednesday, May 30th. They set a “buy” rating and a $240.00 target price for the company. Cowen reissued a “buy” rating on shares of bluebird bio in a report on Monday, June 4th. BidaskClub raised shares of bluebird bio from a “sell” rating to a “hold” rating in a report on Friday, June 15th. Finally, Evercore ISI raised shares of bluebird bio from an “in-line” rating to an “outperform” rating and increased their price objective for the stock from $175.00 to $230.00 in a report on Tuesday, June 19th. Three investment analysts have rated the stock with a sell rating, nine have assigned a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $212.05.
In other bluebird bio news, insider Jeffrey T. Walsh sold 21,500 shares of the firm’s stock in a transaction that occurred on Thursday, August 2nd. The shares were sold at an average price of $152.02, for a total transaction of $3,268,430.00. Following the sale, the insider now directly owns 56,995 shares in the company, valued at approximately $8,664,379.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Alison Cecily Finger sold 259 shares of the firm’s stock in a transaction that occurred on Monday, August 20th. The stock was sold at an average price of $158.07, for a total transaction of $40,940.13. The disclosure for this sale can be found here. Insiders sold a total of 75,086 shares of company stock worth $12,339,862 over the last quarter. 3.00% of the stock is currently owned by corporate insiders.
bluebird bio Company Profile
bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in various clinical studies for the treatment of transfusion- transfusion-dependent ß-thalassemia and severe sickle cell disease.
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.